Trials / Completed
CompletedNCT05893576
A Relative Bioavailability Study of HRS9531 in Healthy Subjects
A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 | Receive a single dose of HRS9531 of original formulation. |
| DRUG | HRS9531 | Receive a single dose of HRS9531 of new formulation. |
Timeline
- Start date
- 2023-05-15
- Primary completion
- 2023-09-04
- Completion
- 2023-09-04
- First posted
- 2023-06-08
- Last updated
- 2023-10-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05893576. Inclusion in this directory is not an endorsement.